Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H L Davis

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
American Journal of Clinical Oncology|December 1, 1988
ECOG phase II trials of MGBG, chlorozotocin, COM multidrug therapy in advanced measurable colorectal cancerH O Douglass, M Lefkopoulou, H L Davis, et al.
Cancer Treatment Reports|August 1, 1977
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agentsD D Von Hoff, M Rozencweig, W T Soper, et al.
Cancer Treatment Reports|July 1, 1983
Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusionR H Earhart, J M Koeller, T E Davis, et al.
Annals of Internal Medicine|November 1, 1979
Risk factors for doxorubicin-induced congestive heart failureD D Von Hoff, M W Layard, P Basa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal primingJ Kovarik, P Bozzotti, L Love-Homan, et al.
Vaccine|August 26, 1999
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeysT R Jones, N Obaldia, R A Gramzinski, et al.
Journal of Clinical Immunology|December 29, 2004
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II studyC L Cooper, H L Davis, M L Morris, et al.
Cancer Research|December 1, 1982
Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patientsR H Earhart, K D Tutsch, J M Koeller, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 15, 1998
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifsA M Krieg, T Wu, R Weeratna, et al.
Wisconsin Medical Journal|May 1, 1988
Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancerR M Hansen, T K Banerjee, H L Davis, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
American Journal of Clinical Oncology|December 1, 1988
ECOG phase II trials of MGBG, chlorozotocin, COM multidrug therapy in advanced measurable colorectal cancerH O Douglass, M Lefkopoulou, H L Davis, et al.
Cancer Treatment Reports|August 1, 1977
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agentsD D Von Hoff, M Rozencweig, W T Soper, et al.
Cancer Treatment Reports|July 1, 1983
Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusionR H Earhart, J M Koeller, T E Davis, et al.
Annals of Internal Medicine|November 1, 1979
Risk factors for doxorubicin-induced congestive heart failureD D Von Hoff, M W Layard, P Basa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal primingJ Kovarik, P Bozzotti, L Love-Homan, et al.
Vaccine|August 26, 1999
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeysT R Jones, N Obaldia, R A Gramzinski, et al.
Journal of Clinical Immunology|December 29, 2004
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II studyC L Cooper, H L Davis, M L Morris, et al.
Cancer Research|December 1, 1982
Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patientsR H Earhart, K D Tutsch, J M Koeller, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 15, 1998
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifsA M Krieg, T Wu, R Weeratna, et al.
Wisconsin Medical Journal|May 1, 1988
Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancerR M Hansen, T K Banerjee, H L Davis, et al.
Pageof 17